BioROSA Technologies creates a biologically-based diagnostic standard of care for Autism Spectrum Disorders.
BioROSA Technologies has raised $745K in total funding. The most recent round was Debt Financing. The last funding was announced in November 2022.
BioROSA Technologies's investors include SOSV, Autism Impact Fund, SOSV SF & NY (Fka IndieBio), Zoic Capital, Bioverge.
BioROSA Technologies is headquartered in Belmont, United States.
BioROSA Technologies creates a biologically-based diagnostic standard of care for Autism Spectrum Disorders.
BioROSA Technologies is at the Debt Financing stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"BioROSA Technologies — Funding & Investors." VCBacked, November 22, 2022, https://www.vcbacked.co/company/biorosa-technologies. Accessed August 14, 2026.
VCBacked. (2022). BioROSA Technologies — Funding & Investors. Retrieved August 14, 2026, from https://www.vcbacked.co/company/biorosa-technologies
{{cite web |title=BioROSA Technologies — Funding & Investors |url=https://www.vcbacked.co/company/biorosa-technologies |website=VCBacked |access-date=August 14, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated